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The SSAI fully supports the suspension of hydroxyethyl-starch
solutions commissioned by the European Medicines Agency
The Coordination Group for Mutual Recognition and Decentralised
Procedures (CMDh) of the European Medicines Agency (EMA) has
recently endorsed the recommendation by EMA’s Pharmacovigilance
Risk Assessment Committee (PRAC) to suspend the marketing
authorisations of hydroxyethyl-starch (HES) solutions across the
European Union, as well as in Iceland, Liechtenstein and Norway.1
This has prompted a response from the president of the German
Society of Anaesthesiology and Intensive Care Medicine (DGAI) who
has invited national anaesthesia societies across Europe to endorse a
letter to the EMA and to the European Commission, denouncing the
suspension of HES (Prof. Dr. med. Bernhard Zwißler President of the
DGAI, personal communication).
In this paper, written on behalf of the Board of The Scandinavian
Society of Anaesthesiology and Intensive Care Medicine (SSAI) and
the national societies of Iceland, Denmark, Finland, Sweden and Nor-
way, we explain why the SSAI fully supports the recommendation to
suspend the marketing authorisation of HES solutions.
HES solutions are intravenous fluid products (colloids) that, until
recently, were commonly used in clinical practice.2 HES solutions
have, however, been found to be associated with adverse outcomes
for patients, including acute kidney injury3-5 and increased risk of
bleeding.6 In a recently published, high-quality systematic review of
42 randomised clinical trials (11 399 patients), HES products were
associated with a 59% increased risk of acute kidney injury, and a
32% increased risk of renal replacement therapy compared to other
intravenous fluids.7 Importantly, these adverse events were con-
firmed in all patient populations independent of the dosage and type
of HES used. Moreover, a 2013 Cochrane review of randomised clin-
ical trials found no evidence that resuscitation with colloids
improved outcome in surgical patients, including patients with burns
and trauma.8 Importantly, patients who received HES solutions had
increased mortality. These high-quality data underline that use of
HES as volume replacement in patient populations relevant to anaes-
thetists and intensivists, including surgical patients and critically ill
patients, is associated with harm, including acute kidney injury,
bleeding and death.
Following the raised concerns about the safety of HES, some
research groups and societies have continued to recommend use of
HES solutions based on studies with serious methodological flaws
and with significant financial and academic conflict of interests.9,10
Recently, it was pointed out that an earlier decision by the EMA
(2013) to restrict the use of HES to non-septic patients with haem-
orrhagic shock was not being followed in many countries, and that
HES solutions continue to be used in populations at high risk, eg,
postpartum haemorrhage.11 In an appeal to the World Health Orga-
nization, the authors called for a global ban of HES. If primum non
nocere (first do no harm) is to be our guiding principle, this is the log-
ical next step.
In summary, there is high-quality evidence that use of HES solu-
tions as volume replacement in critically ill patients in general,
including surgical patients and ICU patients increases the risk of
adverse outcomes, including acute kidney injury, bleeding and
death.5,7,8 Also, there are no valid data indicating that HES solutions
are superior to crystalloid solutions in any population. Therefore, the
use of HES needs to stop immediately. Thus, the SSAI and the Nor-
dic national anaesthesia and intensive care societies fully support the
suspension of HES solutions as suggested by the EMA.
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